Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Trial details
- Registry ID
- NCT03608033
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyNCT03608033 | Omeros Corporation | Phase 3 | Terminated | 2024-01-12Actual |
| Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesNCT02222545 | Omeros Corporation | Phase 2 | Completed | 2020-01-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |